SARS-COV-2 IgG antibody response in pregnant women at delivery

Tsatsaris, Vassilis; Mariaggi, Alice-Andrée; Launay, Odile; Couffignal, Camille; Rousseau, Jessica; Ancel, Pierre Yves; Marcault, Estelle; Ville, Yves; Cordier, Anne-Gaël; Vivanti, Alexandre; Carrara, Julie; Luton, Dominique; Dommergues, Marc; Borie, Constance; Kayem, Gilles; Alessandrini, Vivien; Lecomte, Laurence; Meritet, Jean François; Leruez-Ville, Marianne; Goffinet, François; Dubois, Claire; Picone, Olivier; Vauloup Fellous, Christelle

BACKGROUND: The prevalence of COVID-19 infection during pregnancy is not known. COVIPREG is a prospective French multicenter study to assess the seroprevalence at the time of delivery and the maternal and neonatal impact of COVID-19 infection during pregnancy. In order to study factors associated with poor outcomes after COVID-19 Infection during pregnancy and adapt the sample size of the study, a preliminary assessment of the prevalence of SARS-CoV-2 IgG was planned after 500 inclusions in a one perinatal center of Paris area. OBJECTIVES: To assess the prevalence of SARS-CoV-2 IgG antibody response in pregnant women at the time of delivery during the COVID-19 pandemia. STUDY DESIGN: A prospective observational study at Cochin hospital (Level III maternity). Patients admitted for delivery were offered to participate to the study. Each patient participating to the study was tested for anti-SARS-CoV-2-IgG antibodies using a commercially available ELISA. RESULTS: Among the 529 patients included in the COVIPREG study between April 29 and June 26, 529 were assessed for SARS-CoV-2 IgG antibody response and 25 had a positive test, ie 4.7 % with a confidence interval at 95 % [3.0 %–6.9 %]). CONCLUSIONS: Four months after the beginning of the infection in Paris, the seroprevalence of SARS-CoV-2 IgG in pregnant women at the time of delivery is low. Studies evaluating the impact of COVID-19 infection during pregnancy should take this information in account in order to adapt the sample size.